4.2 Medication Administration, Dosages, High-Alert Drugs & Pharmacovigilance

4.2 Medication Administration, Dosages, High-Alert Drugs & Pharmacovigilance

Quick Answer: Safe medication administration demands unyielding adherence to the Ten Rights, strict double-checking of high-alert medications (APINCH), and flawless mathematical execution of dosage and gravity drip calculations using the formula: $\text{Flow Rate (gtt/min)} = [\text{Volume (mL)} \times \text{Drop Factor (gtt/mL)}] / \text{Time (min)}$. Intramuscular delivery requires landmark-based site selection—prioritizing the ventrogluteal site in adults and vastus lateralis in infants—with Z-track displacement for irritating agents. In Ghana, suspected adverse drug reactions are reported to the Food and Drugs Authority (FDA) through its Med Safety app or its adverse-reaction reporting form.

---

The Ten Rights of Medication Administration

Administering medications is a high-liability independent and collaborative nursing function. The classic "Five Rights" have been expanded into the Ten Rights of Medication Administration to build systemic barriers against clinical error:

1. Right Patient: Verify identity using at least two unique person-specific identifiers (e.g., patient's full name, hospital identification/folder number, date of birth). Never rely on room number or bed assignment. In conscious patients, ask them to state their name; in pediatric or unconscious patients, verify against the medical wristband.
2. Right Drug: Conduct three independent label checks: (1) when retrieving the container from storage/pharmacy, (2) when preparing or drawing up the medication, and (3) at the patient's bedside immediately prior to administration. Verify the chemical generic name against the Medication Administration Record (MAR).
3. Right Dose: Confirm the prescribed dose aligns with standard therapeutic ranges. Perform independent verification of pediatric or weight-based calculations.
4. Right Route: Ensure the pharmaceutical formulation is approved for the ordered route (e.g., never administer oral liquid formulations intravenously, or sustained-release capsules crushed via NGT).
5. Right Time: Administer within the institution's approved therapeutic window (typically within 30 minutes before or after scheduled time). Account for circadian rhythms and food interactions (e.g., gastric mucosal irritants taken with meals; antacids separated from fluoroquinolones).
6. Right Documentation: Record administration on the MAR immediately after the dose is given—never prior to administration. Document the dose, exact time, anatomic route/site, and clinical parameters (e.g., apical pulse prior to digoxin, blood pressure prior to ACE inhibitors).
7. Right Reason / Indication: Confirm the clinical indication for the prescription. A nurse must understand why the specific drug is indicated for this specific patient.
8. Right Response (Assessment): Evaluate therapeutic efficacy and monitor for adverse effects, drug interactions, or toxicity (e.g., measuring post-analgesic pain scores, blood glucose following insulin).
9. Right Patient Education: Inform the patient regarding the drug's purpose, expected therapeutic effects, potential side effects, and dietary precautions in culturally accessible language.
10. Right to Refuse: A mentally competent adult retains the legal right to refuse any medical treatment. The nurse must explore the patient's rationale, explain the physiological consequences of refusal, document the event, and notify the prescribing physician.

---

Enteral and Parenteral Administration Routes

Routes are chosen based on drug bioavailability, onset requirements, and patient clinical status.

                                  ROUTES OF ADMINISTRATION
                                             |
                   +-------------------------+-------------------------+
                   |                                                   |
            ENTERAL ROUTES                                     PARENTERAL ROUTES
     (GI Tract: Oral, Sublingual,                             (Bypasses GI Tract:
      Buccal, Rectal, Tube)                                    SC, IM, IV, ID)

Enteral Routes

• Oral (PO): Most convenient and cost-effective. Absorbed across gastric and intestinal mucosa, undergoing variable hepatic first-pass metabolism.
• Sublingual (SL) & Buccal: Placed under the tongue or in the buccal pouch between cheek and gum. Highly vascular mucosa allows direct venous absorption into systemic circulation, bypassing hepatic first-pass metabolism (e.g., sublingual nitroglycerin/glyceryl trinitrate for acute angina). Patients must not chew, swallow, or consume fluids until the tablet completely dissolves.

Parenteral Routes: Intramuscular (IM) Injection Anatomy

Intramuscular injections deliver medications deep into vascularized muscle tissue, providing faster absorption than subcutaneous injections while accommodating larger fluid volumes (up to 3–4 mL in well-developed sites).

                                  IM INJECTION SITES
                                          |
        +---------------------------------+---------------------------------+
        |                                 |                                 |
  VENTROGLUTEAL                   VASTUS LATERALIS                       DELTOID
- Safest adult site             - Preferred: infants/toddlers          - Small volumes (<=1 mL)
- Gluteus medius/minimus        - Anterolateral middle third thigh     - 2-3 fingers below acromion
- No major nerves/vessels       - Large muscle bulk                    - Vaccines, toxoids

1. Ventrogluteal Site (Gluteus Medius and Minimus):
   • Anatomy & Safety: The safest, most evidence-based site for adults and walking children. Deep muscle tissue, free of major neural or vascular trunks, and covered by a thinner layer of adipose tissue than the buttocks.
   • Landmarking: Place the palm of the hand over the patient's greater trochanter (right hand for left hip; left hand for right hip). Point the index finger toward the anterior superior iliac spine (ASIS) and spread the middle finger posteriorly along the iliac crest toward the buttock. The injection site is the center of the triangular "V" formed between the index and middle fingers.
2. Vastus Lateralis Site:
   • Anatomy & Safety: Thick, well-developed muscle on the anterolateral aspect of the thigh. The site of choice for infants, neonates, and children under 2 years of age prior to significant ambulation, and the standard site for routine childhood immunizations in Ghana.
   • Landmarking: Divide the distance between the greater trochanter of the femur and the lateral femoral condyle of the knee into vertical thirds; inject into the outer lateral middle third.
3. Deltoid Site:
   • Anatomy & Safety: Easily accessible muscle on the lateral upper arm. Restricted to small injection volumes (≤ 1.0 mL). Proximity to the radial nerve, deep brachial artery, and acromion process carries risks of neurovascular damage if landmarking is flawed.
   • Landmarking: Locate the lower border of the acromion process. Form an inverted triangle 2 to 3 fingerbreadths (3–5 cm) below the acromion; inject into the center of the muscle belly.
4. Dorsogluteal Site (Historical Warning):
   • Deprecated Practice: The traditional upper outer quadrant of the buttock is clinically obsolete and strongly discouraged. Anatomical studies confirm unpredictable sciatic nerve trajectories and superior gluteal artery proximity, which can cause permanent sciatic nerve palsy, foot drop, and hematomas.

Step-by-Step Z-Track Technique

The Z-track technique is mandatory for administering deep intramuscular medications that cause severe tissue irritation, necrosis, or permanent cutaneous staining (e.g., iron dextran, haloperidol, hydroxyzine):

Step 1: Pull skin/subcutaneous tissue laterally (1 to 1.5 inches) and hold.
Step 2: Insert needle at 90-degree angle; inject medication slowly (10 sec/mL).
Step 3: Wait 10 seconds to allow drug dispersion in muscle.
Step 4: Withdraw needle and simultaneously release displaced skin.
Result: Broken needle track traps medication within muscle belly, preventing back-leakage.

• Procedure Details: Pull the overlying skin and subcutaneous tissue approximately 1 to 1.5 inches (2.5–3.8 cm) laterally or downward with the ulnar border of the non-dominant hand. Maintain firm traction while inserting a long needle (1.5 to 2 inches, 21–22G) at a 90-degree angle into the muscle. Inject the drug slowly (10 seconds per mL), wait 10 seconds to allow muscle fibers to accommodate the fluid, then withdraw the needle and release the retracted tissue simultaneously. The tissue planes slide across one another, sealing the puncture track.
• Crucial Rule: Never massage the injection site, as rubbing forces the drug into superficial subcutaneous planes.

---

Dosage Calculations and Gravity IV Infusion Rates

In many resource-constrained clinical settings across Ghana, electronic volumetric infusion pumps are reserved for critical care units. Bedside nurses must master gravity-fed intravenous drip rate calculations.

Standard Gravity Infusion Formula

$\text{Flow Rate (drops/minute)} = \frac{\text{Total Volume to Infuse (mL)} \times \text{Drop Factor (gtt/mL)}}{\text{Infusion Time in Minutes}}$

• Macrodrip Sets (Adult): Calibrated to deliver 10, 15, or 20 drops per mL (standard blood giving sets and crystalloid lines in Ghana commonly use 15 or 20 gtt/mL).
• Microdrip Sets (Pediatric / Soluset): Uniformly calibrated to deliver 60 drops per mL (where 60 gtt/min = 60 mL/hr; drops per minute equals mL per hour).

Clinical Calculation Example

Clinical Scenario: A physician orders 1,000 mL of 0.9% Normal Saline to infuse intravenously over 8 hours for a dehydrated adult. The available IV administration set has a drop factor of 15 gtt/mL. Calculate the required drip rate in drops per minute.

1. Convert hours into minutes: $8 \text{ hours} \times 60 \text{ minutes} = 480 \text{ minutes}$.
2. Substitute values into the formula:

$\text{Flow Rate} = \frac{1000 \text{ mL} \times 15 \text{ gtt/mL}}{480 \text{ minutes}} = \frac{15000}{480} = 31.25 \text{ gtt/min}$

1. Round to the nearest whole integer: 31 drops per minute (approximately 1 drop every 2 seconds).

Pediatric Weight-Based Dosage Calculations

Pediatric dosing requires absolute precision, as minor milligram calculation errors can lead to toxicity or fatal overdoses.

$\text{Total Daily Dose} = \text{Child's Weight (kg)} \times \text{Dosage per kg (mg/kg/day)}$ $\text{Individual Dose} = \frac{\text{Total Daily Dose}}{\text{Number of Doses per Day}}$

Worked Clinical Example: A 4-year-old child weighing 16 kg is prescribed oral Amoxicillin suspension at 40 mg/kg/day in three equally divided doses (every 8 hours). The pharmacy dispenses Amoxicillin syrup with a concentration of 125 mg / 5 mL.

• Total daily dose: $16 \text{ kg} \times 40 \text{ mg/kg/day} = 640 \text{ mg/day}$.
• Dose per administration: $640 \text{ mg} / 3 \approx 213.3 \text{ mg}$ per dose.
• Liquid volume to administer: $\frac{213.3 \text{ mg}}{125 \text{ mg}} \times 5 \text{ mL} = 1.706 \times 5 \approx 8.5 \text{ mL}$ every 8 hours.

---

High-Alert Medications: The APINCH Framework

High-alert medications bear an elevated risk of causing significant patient harm, disability, or death when administered incorrectly. Clinical errors with these agents are not necessarily more frequent, but the physiological consequences are catastrophic.

+-----------------------------------------------------------------------------------------+
|                                THE APINCH CLASSIFICATION                                |
+---+------------------------------------+------------------------------------------------+
| A | Anti-infectives                    | Aminoglycosides (gentamicin), IV vancomycin,   |
|   |                                    | amphotericin B (ototoxicity, nephrotoxicity).  |
+---+------------------------------------+------------------------------------------------+
| P | Potassium & Concentrated           | Concentrated Potassium Chloride (KCl), 3% NaCl |
|   | Electrolytes                       | hypertonic saline, IV Magnesium sulfate.       |
+---+------------------------------------+------------------------------------------------+
| I | Insulin                            | Subcutaneous and intravenous regular, lispro,  |
|   |                                    | glargine (severe hypoglycemic coma/death).     |
+---+------------------------------------+------------------------------------------------+
| N | Narcotics & Sedatives              | Morphine, pethidine, fentanyl, hydromorphone,  |
|   |                                    | midazolam (fatal respiratory depression).      |
+---+------------------------------------+------------------------------------------------+
| C | Chemotherapy Agents                | Cytotoxic antineoplastic drugs (severe bone    |
|   |                                    | marrow suppression, extravasation necrosis).   |
+---+------------------------------------+------------------------------------------------+
| H | Heparin & Anticoagulants           | Unfractionated heparin, LMWH, warfarin, DOACs  |
|   |                                    | (spontaneous intracranial hemorrhage).         |
+---+------------------------------------+------------------------------------------------+

Universal Ban on IV Push Potassium Chloride

[!CAUTION] Critical Safety Rule: Never Administer Potassium Chloride IV Push! Concentrated Potassium Chloride (KCl) administered via direct intravenous bolus, push, or rapid infusion induces immediate, irreversible hyperkalemic myocardial depolarization, producing instantaneous asystole and fatal cardiac arrest. Concentrated KCl must NEVER be stocked in open ward treatment rooms; it must be stored under pharmacy control and diluted thoroughly in large-volume infusion bags (maximum peripheral concentration typically 20–40 mmol/L, infused at a rate not exceeding 10–20 mmol/hour with continuous cardiac monitoring).

Independent Double-Check Protocol

For all high-alert medications, hospitals must enforce an Independent Double-Check: Two qualified registered nurses independently verify the original prescriber's order, check patient identity, perform calculation math separately without sharing figures beforehand, verify vial concentrations and expiration dates, inspect the infusion pump programming or drip rate, and co-sign the MAR.

---

Look-Alike Sound-Alike (LASA) Safety Strategies

Medication dispensing errors frequently occur due to orthographic (visual) or phonetic (auditory) similarities between drug names. Safety protocols include:

1. Tall Man Lettering: The utilization of bold, capitalized typography within a drug's name to visually emphasize distinctive letter sequences (e.g., DOPamine versus DOBUTamine; predniSONE versus predniSOLONE; hydrOXYzine versus hydrALAzine).
2. Physical Segregation: Storing confusingly paired medications in separate bins or non-adjacent shelves with bright, color-coded warning labels.
3. Indication Matching: Writing the explicit clinical diagnosis or indication alongside the drug name on the prescription sheet.

---

Ghana FDA Pharmacovigilance and ADR Reporting

Pharmacovigilance encompasses the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.

The National Regulatory Framework

The Food and Drugs Authority (FDA) of Ghana, which regulates medicines under Part Seven of the Public Health Act, 2012 (Act 851), runs the national pharmacovigilance system and relies on health professionals to report suspected adverse drug reactions and product problems.

                               GHANA FDA PHARMACOVIGILANCE
                                            |
                 +--------------------------+--------------------------+
                 |                                                     |
        SUSPECTED EVENT                                       REPORTING CHANNELS
- Adverse Drug Reactions (ADRs)                      - MedSafety Mobile Application
- Therapeutic treatment failures                     - FDA ADR reporting form (paper/PDF)   
- Substandard or falsified drugs                     - Direct reporting via health facility
- Vaccine events (AEFI)                                institutional focal person

What Must Be Reported

• Any suspected Adverse Drug Reaction (ADR), particularly unexpected, serious, or fatal reactions;
• Suspected therapeutic failure or lack of efficacy (which frequently reveals substandard or falsified medicines in circulation);
• Medication errors and adverse events following immunization (AEFI);
• Adverse reactions associated with herbal remedies, homeopathic products, or blood products.

Reporting Channels

• MedSafety Mobile App: A digital platform launched by the Ghana FDA allowing nurses and doctors to rapidly submit direct electronic adverse event reports from smartphones.
• Paper ADR reporting form: The FDA's paper form is kept in health facilities; completed forms go to the facility's pharmacovigilance focal person or directly to the FDA.